Insulet Corporation vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Acton MA tubeless insulin pump (NASDAQ: PODD) $2.18B FY2024 revenue (+21%); Omnipod 5 automated insulin delivery with Dexcom/Libre integration, type 2 expansion, competing with Medtronic MiniMed and Tandem.
About
Insulet Corporation is an Acton, Massachusetts-based medical device company — publicly traded on the NASDAQ (NASDAQ: PODD) as an S&P 500 Health Care component — developing, manufacturing, and commercializing the Omnipod insulin delivery system: a tubeless, wearable, waterproof insulin pump patch worn directly on the body without tubing connections to a separate controller, automatically delivering insulin to people with type 1 and type 2 diabetes through approximately 5,000 employees globally. In fiscal year 2024, Insulet reported revenues of $2.18 billion (+21% year-over-year), driven by Omnipod 5 (Omnipod's automated insulin delivery — AID — system integrating with Dexcom CGM and Abbott FreeStyle Libre sensors to automatically adjust insulin delivery based on real-time glucose readings without manual user input), which drove international expansion in Europe and adoption in type 2 diabetes patients who previously used multiple daily injections rather than insulin pumps. CEO Jim Hollingshead has accelerated Omnipod's differentiation through the automated insulin delivery positioning: Omnipod 5's algorithm automatically modulates basal insulin rates every 5 minutes based on continuous glucose monitor readings — reducing A1c levels and time-in-hypoglycemia without requiring the user to manually program correction boluses for most scenarios — transforming diabetes management from active self-management to a background automated process that dramatically improves quality of life for insulin-dependent diabetics.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.